Loss-of-function experiments using siRNA or shRNA targeting ILK have demonstrated that knockdown of ILK represses EMT, tumor growth, and metastasis in tongue and prostate cancers through inactivation of the PI3K/AKT pathway134. This evidence concerns the gene ILK and prostate carcinoma.